Evelyne Nguyen

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

Exane SA (Broker) (Exane) is the brokerage division of Exane SA, itself a subsidiary of Verner Investissements SAS in France. Established in 2004 as a joint venture between BNP Paribas and Verner Investissements, the firm is based in Paris and specializes in European equity research and broking activities. Exane has research centers in Paris and London which are supported by a team of economists and strategists.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Handicare AS manufactures and supplies technical aids for the elderly and disabled people. Its products include wheelchairs, stair lifts, patient handling and bathroom safety products, personal transfer, and automobile adaptation solutions. The company was founded on November 11, 1992 and is headquartered in Moss, Norway.

Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium.

International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA.

bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC.

Humanim, Inc. provides human services and workforce development resources. Its services include mental health, vocational, neuro-rehabilitation, developmental disabilities and deaf services. The company was founded in 1971 and is headquartered in Columbia, MD.

Bionest Partners, Inc. provides consulting services to the medical industry. The firm offers expertise in all aspects of the life sciences including medical devices, diagnostics, research and development, marketing, corporate development, and personal medicine strategy. The company was founded by Robert J. Easton in 2003 and is headquartered in New York, NY.

Optegra UK Ltd. provides ophthalmic services. It offers treatment for cataract, age-related macular degeneration, corneal cross linking and keratoconus and glaucoma. The firm operates hospitals in Birmingham, London, Manchester, Surrey, Solent and Yorkshire. The company was founded in 2006 and is headquartered in London, the United Kingdom.

Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France.

Spineart SA operates as a medical device company. The firm designs, develops and promotes solutions to spine surgeons, operating room teams, and patients. It serves in the area of minimally invasive surgery, motion preservation, fusion, biologics, and fractures treatment. The company was founded by Jérôme Levieux and Stéphane Mugnier in 2005 and is headquartered in Geneva, Switzerland.

Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines.

Equipe Zorgbedrijven Nederland BV operates a chain of private clinics. Its specialized in hand and wrist, orthopedic, cosmetic, vaginal, and revalidation care. The company was founded by Jak Dekker in 1995 and is headquartered in Eindhoven, the Netherlands.

Medcura, Inc. develops novel line of hemostatic and wound treatment products. The firm?s products include vascular gel-e, nuisance bleed, chronic wound, and surgical gel-e. The company was founded by Matthew Dowling in January 2013 and is headquartered in Riverdale, MD.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Heilig Hart Ziekenhuis is a hospital located in Lier, BE. The hospital offers parking, and information about rates and intended users can be found on their website. The hospital staff works to provide care for patients during emergency admissions or day and multi-day stays. Patients can also find information about their stay on the hospital's website. The CEO of the Belgian company is Stefaan Vansteenkiste.

Part of Optegra Global Ltd., Optegra International Ltd. functions as an investment holding British company. The private company is based in Hildenborough, UK and was founded in 2016.

Part of Biophytis SA, Biophytis, Inc. operates as a clinical-stage biotechnology company which develops therapeutics for aging and improving functional outcomes. The private company is based in Newark, DE.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.

Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA.